Nymirum

Nymirum specializes in RNA-targeted small molecule drug discovery, leveraging the dynamics and atomic scale structure of RNA to identify novel druggable conformations. The company collaborates with major pharmaceutical firms to expedite RNA drug discovery processes. As the first company to focus on RNA with small molecules, Nymirum serves clients with deep biological expertise in specific disease areas or biological pathways, offering a comprehensive partnership for RNA discovery. The business model revolves around forming strategic partnerships with pharmaceutical companies, providing expertise in RNA dynamics to enhance drug discovery efforts. Nymirum's approach includes high-performance virtual screening and targeting high-resolution RNA dynamic ensembles, aiming to develop highly specific herbicides and pesticides with minimal environmental and human impact. The company operates in the biotech sector, focusing on both human and animal health, acknowledging the significant overlap in pathogenic diseases transmissible between species. Keywords: RNA, small molecule, drug discovery, pharmaceutical, partnerships, biotech, virtual screening, herbicides, pesticides, human health.